Pharma Focus Europe

Velocity Clinical Research Extends Its Operations Into Poland

Thursday, December 07, 2023

Velocity Clinical Research, a renowned organization specializing in clinical research across diverse medical fields, has announced its expansion into Poland through the acquisition of its inaugural center, ClinMedica Research. Positioned in Skierniewice, strategically located between Warsaw and Łódź, this center signifies the first step in Velocity's plan to acquire key research centers throughout Poland by the end of the year. ClinMedica Research, under the leadership of Dr. Grzegorz Kania, is highly esteemed for its rapid recruitment processes, research quality, and exceptional patient care, earning recognition from sponsors and contract research organizations (CROs) as a premier research facility in the country.

Dominic Clavell, General Manager Europe at Velocity, expressed the company's firm commitment to its European expansion initiated in July 2022. Highlighting Poland's importance as a strategic market with high patient recruitment rates for clinical trials, Clavell sees the acquisition of ClinMedica as the initial step in establishing a network of top-notch research centers in Poland. This move aims to strengthen Velocity's regional presence and contribute to its broader goal of achieving critical mass in the UK and Europe, enabling independent and diverse research recruitment.

Dr. Agnieszka Gackowska, formerly Global Head Site Solutions at Parexel and a certified physician, has joined Velocity as Vice President and Country Head for Poland. Gackowska emphasized that Velocity's expansion in Poland aligns with a global outlook but emphasizes local impact in clinical trials. The goal is to extend trial accessibility to individuals residing outside major cities, offering them opportunities for innovative treatment methods. Gackowska envisions the presence of a global company with a patient-centric focus as a catalyst for creating career opportunities for local doctors, preventing the loss of Polish talents to larger markets.

Velocity's integrated network spans over 80 locations across the US, UK, Germany, and now Poland, with an additional IT center in Hyderabad, India. With a total of five centers in the UK, four in Germany, and the newly acquired Polish center, Velocity boasts access to over 220 principal investigators covering various therapeutic areas and a database of over one million patients. The company's centralized infrastructure and common IT solutions ensure seamless operation of the patient recruitment system and reliable high-quality data collection. This integrated approach facilitates sponsors and CROs in gaining easier access to centers and clinical trial investigators on an international scale.

 

Source: globenewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva